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Summary
AIMS OF THE STUDY: Atezolizumab is an approved ther-
apy for urothelial carcinoma based on results from the
IMvigor 210 and IMvigor211 phase II and III trials. The
global SAUL study evaluated atezolizumab in a broader
patient population more representative of real-world pop-
ulations. Among approximately 1000 patients treated in
SAUL, 25 were treated in Swiss oncology centres. We
evaluated outcomes in these patients to provide a better
understanding of atezolizumab treatment for urinary tract
carcinoma in Swiss clinical practice.
METHODS: Eligible patients had locally advanced or
metastatic urothelial or non-urothelial urinary tract carcino-
ma that had progressed during or after one to three pri-
or therapies for inoperable, locally advanced or metastatic
disease. Patient populations typically excluded from clini-
cal trials (e.g., patients with renal impairment, treated cen-
tral nervous system [CNS] metastases, stable controlled
autoimmune disease or Eastern Cooperative Oncology
Group performance status 2) were also eligible. All pa-
tients received atezolizumab 1200 mg every 3 weeks un-
til loss of clinical benefit or unacceptable toxicity. The pri-
mary endpoint was safety. Secondary endpoints included
overall survival (OS), overall response rate (ORR) and dis-
ease control rate (DCR).
RESULTS: All 25 Swiss patients had previously received
a gemcitabine/platinum doublet. Disease had progressed
within 12 months of platinum-based therapy in all but one
patient, and 19 (76%) had received one prior line of ther-
apy for metastatic disease. The median duration of ate-
zolizumab therapy was six cycles (range 1–27) corre-
sponding to 3.6 months. Five patients (20%) had received
>20 cycles and four (16%) remained on treatment at the
data cut-off. Grade 3 adverse events (AEs) occurred in 13
patients (52%) and were considered to be treatment-re-
lated in four patients (16%; liver enzyme increases, mus-
culoskeletal pain, diverticulitis and autoimmune hepatitis).
There was one grade 4 AE (hypercalcaemia) and no
grade 5 AEs. After median follow-up of 17.3 months, me-
dian OS was 7.9 months (95% confidence interval [CI]
5.3–not evaluable), the 1-year OS rate was 47% (95% CI
27–65%), the ORR was 12% (95% CI 3–31%) and the
DCR was 40% (95% CI 21–61%). Durable clinical bene-
fit (>1 year on treatment) was observed in seven patients
(28%), including one with CNS metastases and one with
small-cell carcinoma.
CONCLUSIONS: Atezolizumab is an active treatment op-
tion for platinum-pretreated urinary tract carcinoma, in-
cluding patients with conditions that typically exclude them
from clinical trials. (Trial registration no.: NCT02928406)
Keywords: atezolizumab, urinary tract carcinoma, PD-
L1, immunotherapy, Switzerland
Introduction
Platinum-based chemotherapy has been the standard treat-
ment for metastatic urothelial cancer for many years. Re-
sponse rates to platinum-based treatment are fairly good,
but lasting responses are rare [1]. However, treatment op-
tions have expanded rapidly in recent years with the in-
troduction of immunotherapeutic agents into clinical prac-
tice [2]. There are now five agents targeting programmed
cell death ligand 1 (PD-L1) or programmed cell death-1
(PD-1) that are approved as treatment for urothelial car-
cinoma after progression on platinum-based chemothera-
py: avelumab, atezolizumab, durvalumab, nivolumab and
pembrolizumab [3]. Atezolizumab, the first of these agents
to be approved, is a humanised monoclonal antibody that
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binds selectively to PD-L1. Regulatory approval of ate-
zolizumab as second-line treatment for metastatic urothe-
lial carcinoma was based on results from the IMvigor210
and IMvigor211 trials [4–6]. In the IMvigor211 phase III
trial, median overall survival (OS) was 8.7 months and the
overall response rate was 13% [6]. The subsequent single-
arm SAUL study (Clinicaltrials.gov NCT02928406) eval-
uated atezolizumab in a broader patient population (pre-
dominantly platinum pretreated) with the aim of improving
understanding of the safety and efficacy of atezolizumab
in understudied populations typically excluded from trials
designed with regulatory intent. This multinational study
enrolled patients from 32 countries across Europe, Asia,
South America, Australia and Canada. Median OS in the
overall population of SAUL was 8.7 months (95% con-
fidence interval [CI] 7.8–9.9 months). In the subgroup of
643 patients considered to be ‘IMvigor211-like’ (i.e., ex-
cluding special populations of patients that were ineligible
for IMvigor211, such as those with Eastern Cooperative
Oncology Group [ECOG] performance status 2, autoim-
mune disease, non-urothelial histology, etc.), median OS
was 10.0 months (95% CI 8.8–11.9 months).
These results provide a robust and reassuring indication of
treatment outcomes in atezolizumab-treated patients pre-
senting in everyday practice across a wide range of health-
care systems with varying treatment practices. However,
there is considerable variation in medical care between ge-
ographical regions and clinical outcomes may differ sub-
stantially between different healthcare systems with dif-
ferent guidelines and practices. Every year in Switzerland,
approximately 1100 patients are diagnosed with invasive
bladder cancer and more than 500 die from this disease [7].
Data are limited on clinical outcomes in patients receiv-
ing systemic therapy for metastatic urinary tract carcinoma
in Swiss clinical practice. Therefore, we interrogated the
SAUL dataset with the aim of understanding outcomes in
patients treated with atezolizumab for urinary tract carci-
noma in the Swiss healthcare setting, and compared these
results with findings in the global population treated in the
SAUL study.
Materials and methods
The design of the SAUL study has been described in detail
previously [8]. In summary, eligible patients had locally
advanced or metastatic measurable and/or non-measurable
urothelial or non-urothelial urinary tract carcinoma, ECOG
performance status ≤2 and had experienced disease pro-
gression during or following one prior platinum- or non-
platinum-based treatment for inoperable, locally advanced
or metastatic disease (subsequently amended in May 2017
to allow up to three prior platinum- or non-platinum-based
treatments for inoperable, locally advanced or metastatic
disease). Patients whose disease relapsed within 12 months
of (neo)adjuvant treatment were also eligible, as were pa-
tients with treated asymptomatic central nervous system
(CNS) metastases, ongoing steroid treatment at baseline,
stable controlled autoimmune disease or renal impairment
(creatinine clearance ≥15 ml/min). Patients received ate-
zolizumab 1200 mg intravenously every 3 weeks until in-
vestigator-assessed loss of clinical benefit, unacceptable
toxicity, patient or investigator decision to discontinue
therapy or death, whichever occurred first. Patients were
allowed to continue atezolizumab after meeting Response
Evaluation Criteria in Solid Tumours (RECIST) version
1.1 criteria for disease progression, providing all of the fol-
lowing criteria were met: evidence of clinical benefit (de-
fined as the stabilisation or improvement of disease-relat-
ed symptoms) as assessed by the investigator; absence of
symptoms and signs (including worsening of laboratory
values) indicating unequivocal progression of disease; no
decline in ECOG performance status that could be attrib-
uted to disease progression; and absence of tumour pro-
gression at critical anatomical sites (e.g., leptomeningeal
disease) that could not be readily managed and stabilised
by protocol-allowed medical interventions before repeat
dosing.
The primary endpoint was safety, defined as the nature,
severity, duration, frequency and timing of adverse events
graded according to National Cancer Institute Common
Terminology Criteria for Adverse Events version 4.0. Sec-
ondary endpoints included OS, investigator-assessed pro-
gression-free survival (PFS) (per RECIST version 1.1),
overall response rate (per RECIST version 1.1), disease
control rate (defined as the sum of patients achieving a
complete or partial response, or stable disease for ≥4
weeks), and duration of response.
Ethical approval for the study (ID 2016-01933) was ob-
tained from the Cantonal Ethics Commission (KEK) in
Bern, the Ethics Commission Northwest and Central
Switzerland (EKNZ) in Basel, the Commission Cantonale
d’Ethique de la Recherche sur l’être humain (CCER) in
Geneva, the Comitato Etico Cantonale (CE-TI) in Ticino
and the Cantonal Ethics Commission Zurich (CEC) in
Zurich.
Results
Among 997 patients treated in the global SAUL study, 25
patients were treated in one of seven Swiss oncology cen-
tres (Kantonsspital Graubünden [Chur], Inselspital Bern,
Istituto Oncologico della Svizzera Italiana [Bellinzona],
Kantonsspital Winterthur, Universitätsspital Basel,
Luzerner Kantonsspital and Hôpitaux Universitaires
Genève). The enrolment period for the overall study popu-
lation was 30 November 2016 to 16 March 2018; patients
in the Swiss subgroup were enrolled between 6 February
2017 and 30 October 2017.
Baseline characteristics of the Swiss subgroup are shown
alongside the global population in table 1. The Swiss sub-
group was slightly older than the global population in
terms of both median age (70 vs 68 years, respectively) and
the proportion aged ≥70 years (56% vs 23%, respectively).
In the Swiss population, 16 patients (64%) were consid-
ered to be ‘IMvigor211-like’, eight patients (32%) repre-
sented populations typically excluded from clinical trials
but of particular interest in the SAUL study, and the re-
maining patient had not experienced disease progression
on or within 12 months of platinum-based therapy. All
three patients with non-urothelial histology (non-IMvig-
or211-like) had small-cell carcinoma.
The majority of patients (76%) received atezolizumab as
second-line therapy, with the remainder treated following
only neoadjuvant or adjuvant chemotherapy (counted as 0
prior lines for the purposes of eligibility). Although pa-
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tients treated in later lines were eligible for enrolment in
SAUL after protocol amendment 4 in May 2017, recruit-
ment in Switzerland was almost complete by this time. All
25 patients had previously received gemcitabine/platinum
combinations (16 patients [64%] with carboplatin; nine
[36%] with cisplatin). Additionally, three patients (12%)
had received etoposide during their prior treatment.
Eight patients (32%) had never smoked (5/16 men [31%]
and 3/9 women [33%]), 10 (40%) were former smokers
(seven men [44%], three women [33%]) and seven (28%)
were current smokers (four men [25%] and three women
[33%]). The mean duration of smoking was 33 years (38
[range 15–60] years in men and 24 [range 5–47] years in
women).
Treatment exposure
The median duration of follow-up at the data cut-off (16
September 2018) was 17.3 months (95% CI 15.4–18.1
months) in the Swiss subgroup. At this time, four patients
(16%) in the Swiss subgroup remained on treatment (fig.
1). Among the 21 patients who had discontinued ate-
zolizumab, the large majority (n = 16, 64% of all 25 pa-
tients) stopped treatment because of disease progression.
Two patients (8%) discontinued because of adverse events,
two (8%) at the patient’s request and one (4%) on the de-
cision of the treating physician after resection of residual
disease on atezolizumab and complete response.
In the Swiss subgroup, patients had received a median
of six cycles (range 1–27), corresponding to 3.6 months
(range 0–17.9 months) at the time of the data cut-off. Five
patients (20%) received >20 cycles.
Safety
An overview of safety results in the Swiss subgroup is pro-
vided in table 2, together with results from the global pop-
ulation and the subgroups corresponding to the ‘IMvig-
or211-like’ population. In the Swiss subgroup, there were
no grade 5 (fatal) adverse events, one patient experienced
a grade 4 adverse event (hypercalcaemia) and 13 patients
(52%) experienced grade 3 adverse events (four cases of





Median age, years (range) 70 (43–81) 68 (34–93)
Age category, n (%) ≥65 years 22 (88) 620 (62)
≥70 years 14 (56) 227 (23)
≥75 years 7 (28) NR
≥80 years 1 (4) 78 (8)
Male, n (%) 16 (64) 772 (77)
Smoking history, n (%) Current 7 (28) 167 (17)
Former 10 (40) 503 (50)
Never 8 (32) 327 (33)
PD-L1 expression score, n (%)* IC 0 6 (24) 243 (24)
IC 1 11 (44) 421 (42)
IC 2/3 8 (32) 264 (26)
Missing 0 69 (7)
Disease location†, n (%) Bladder 19 (76) 744 (75)
Renal pelvis 5 (20) 122 (12)
Ureter 1 (4) 97 (10)
Urethra 0 10 (1)
Stage IV at diagnosis, n (%) 17 (68) 488 (49)
Prior systemic anti-cancer therapy‡, n (%) Total 25 (100) NR
Neoadjuvant 3 (12) NR
Adjuvant 5 (20) NR
Palliative 19 (76) NR
Number of prior lines for metastatic disease§, n (%) 0 6 (24) 382 (38)
1 19 (76) 543 (54)
2 0 52 (5)
3 0 20 (2)
ECOG performance status at screening, n (%) 0 13 (52) 427 (43)
1 11 (44) 469 (47)
2 1 (4) 101 (10)
Non-urothelial or mixed histology|| 3 (12) 47 (5)
Renal impairment (GFR <30 ml/min) 2 (8) 46 (5)
History of autoimmune disease 1 (4) 35 (4)
CNS metastases 1 (4) 14 (1)
Ongoing steroid use at baseline 0 40 (4)
HIV positive 0 2 (<1)
CNS = central nervous system; ECOG = Eastern Cooperative Oncology Group; GFR = glomerular filtration rate; HIV = human immunodeficiency virus; NR = not reported; PD-L1
= programmed cell death ligand 1 * PD-L1 expression was tested using the Ventana SP142 PD-L1 immunohistochemistry assay (Ventana Medical Systems, Tucson, AZ, USA).
IC 0 = PD-L1 expression on <1% of tumour-infiltrating immune cells; IC 1 = PD-L1 expression on ≥1% but <5% of tumour-infiltrating immune cells; IC 2/3 = PD-L1 expression on
≥5% of tumour-infiltrating immune cells. † Reported as ‘other’ in 24 patients (2%) of the global population. ‡ Multiple entries possible. § Patients whose disease relapsed within
12 months of (neo)adjuvant treatment were counted (for the purposes of eligibility) as having received first-line treatment for metastatic disease. || All three patients (12%) in the
Swiss subgroup and seven (1%) in the global population had neuroendocrine tumours.
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urinary tract infection, two cases each of fatigue, lung in-
fection, groin pain, musculoskeletal pain, alanine amino-
transferase [ALT] increase and aspartate aminotransferase
[AST] increase, and one case each of autoimmune hepati-
tis, asthenia, nausea, abdominal pain, oedema, cellulitis,
diverticulitis, pyelonephritis, bacterial urinary tract infec-
tion, urosepsis, decreased appetite, hyponatraemia, dys-
pnoea, renal failure, anaemia, Escherichia coli infection
and traumatic haemothorax). Grade 3 adverse events were
considered by the local investigator to be related to ate-
zolizumab treatment in only four patients. The treatment-
related grade 3 adverse events comprised two cases of ALT
and AST increase (also associated with diverticulitis in
one patient), one case of autoimmune hepatitis and one of
musculoskeletal pain. Three patients experienced grade 3
adverse events of special interest for atezolizumab (two
cases each of ALT increase and AST increase, one case
of autoimmune hepatitis). Adverse events that led to ate-
zolizumab treatment discontinuation were ALT increase in
one patient and pneumonitis in one patient.
Efficacy
At the data cut-off date, 15 patients (60%) had died, all
from disease progression (with unknown other cause cited
as the primary cause of death in two patients who died >30
days after the last dose of atezolizumab). Figure 1 provides
details of response over time for each patient together with
information on relevant baseline characteristics. Figure 2
shows OS for the Swiss subgroup (median 7.9 months,
95% CI 5.3 months – not evaluable) and the global pop-
ulation (median 8.7 months, 95% CI 7.8–9.9 months). In
the subgroup of 16 ‘IMvigor211-like’ Swiss patients, me-
dian OS was 18.0 months (95% CI 6.1 months – not evalu-
able), with treatment ongoing in three of these patients.
In the subgroup of 17 patients with a PD-L1 score of IC
0/1 (PD-L1 expression on <5% of tumour-infiltrating im-
mune cells), median OS was 7.8 months (95% CI 2.8–18.0
months); median OS could not be estimated in the eight
patients with a PD-L1 immune score of IC 2/3 (PD-L1 ex-
pression on ≥5% of tumour-infiltrating immune cells).
Among the three patients with small-cell carcinoma, one
patient had a best response of stable disease, PFS of 11.9
months and OS of 13.8 months, one patient died after 1.6
months (before tumour assessment), and the remaining pa-
Figure 1: Swimmer plot of treatment duration, response and clinical outcome. The upper 16 patients represent the IMvigor211-like population.
The lower eight patients represent those subgroups excluded from IMvigor211. The remaining patient did not have comorbidities or character-
istics excluding them from IMvigor211 but had a treatment history atypical of that trial.CNS = central nervous system; ECOG = Eastern Coop-
erative Oncology Group; PD-L1 = programmed cell death ligand 1. IC 0/1 = PD-L1 expression on <5% of tumour-infiltrating immune cells; IC
2/3 = PD-L1 expression on ≥5% of tumour-infiltrating immune cells.
Table 2: Overview of safety by population.










Any grade AE 24 (96) 880 (88) 15 (94) 577 (90)
‒ Grade 3/4 14 (56) 431 (43) 7 (44) 261 (41)
‒ Grade 5 0 37 (4) 0 20 (3)
Treatment-related AE 19 (76) 530 (53) 12 (75) 355 (55)
‒ Grade ≥3 4 (16) 127 (13) 2 (13) 81 (13)
Serious AE 9 (36) 327 (33) 5 (31) 200 (31)
AESI 14 (56) 305 (31) 11 (69) 201 (31)
‒ Grade ≥3 3 (12) 67 (7) 2 (13) 46 (7)
AE leading to treatment discontinuation 2 (8) 57 (6) 2 (13) 37 (6)
Median treatment duration, months (range) 3.6 (0–17.9) 2.8 (0–19) 3.7 (0.8–17.9) 3.5 (NR)
AE = adverse event; AESI = adverse event of special interest; NR = not reported * All patients except those in subgroups excluded from the IMvigor211 phase III trial
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tient had disease progression as best response, PFS of 1.5
months and OS of 2.8 months.
Table 3 summarises all efficacy parameters, showing the
Swiss subgroup, the global population and the IMvig-
or211-like subgroup within both populations. Median PFS
in the Swiss subgroup after events in 21 patients (84%)
was 2.1 months (95% CI 2.0–4.1 months). The 6-month
PFS rate was 31% (95% CI 14–50%) and the 12-month
PFS rate was 18% (95% CI 6–35%). Duration of treatment
(median 3.6 months, mean 6.4 months) can be considered
as an alternative measure of duration of clinical benefit be-
cause all patients continued treatment until loss of clinical
benefit.
Post-progression treatment
Among the 19 patients in the Swiss subgroup in whom dis-
ease progression had been recorded at the time of data cut-
off, 11 (58%) received at least one cycle of atezolizumab
after RECIST-defined disease progression. Four of these
patients received at least five cycles of atezolizumab, and
two of them were still receiving atezolizumab at the data
cut-off date.
Discussion
These are, to our knowledge, the first prospective data
from a Swiss population of patients treated with an im-
mune checkpoint inhibitor for platinum-pretreated urinary
tract carcinoma. In all of the patients, disease had pro-
gressed on or after gemcitabine/platinum-containing thera-
py, representing a situation frequently encountered in clin-
ical practice that remains challenging to manage. These
data also provide information on outcomes in individual
patients with difficult-to-treat disease, such as CNS metas-
tases and neuroendocrine tumours (small-cell carcinoma).
SAUL was designed to gain deeper insight into the safety
of atezolizumab in metastatic urinary tract carcinoma and
its role in special populations, rather than to compare dif-
ferent treatment options.
Findings among the 25 Swiss patients treated in the SAUL
study are generally consistent with results in the overall
population. Baseline characteristics in the Swiss subgroup
were similar to those in the global population, except for
slightly older age and a notable proportion of patients
(12%) with small-cell carcinoma. The safety profile was
consistent with the established safety profile of ate-
zolizumab in urothelial cancer, with a low incidence of
treatment-related grade ≥3 adverse events (including liver
Figure 2: Overall survival (Swiss subgroup and global population).CI = confidence interval; NE = not evaluable; OS = overall survival.






group (n = 16)
Global population IMvig-
or211-like* subgroup (n =
643)
Median OS, months (95% CI) 7.9 (5.3–NE) 8.7 (7.8–9.9) 18.0 (6.1–NE) 10.0 (8.8–11.9)
6-month OS rate, % (95% CI) 64 (42–79) 60 (57–63) 81 (52–94) 65 (61–69)
1-year OS rate, % (95% CI) 47 (27–65) 41 (38–44) 56 (30–76) 46 (41–50)
Median PFS, months (95% CI) 2.1 (2.0–4.1) 2.2 (2.1–2.4) 2.5 (2.0–6.1) 2.3 (2.2–2.6)
Overall response, n (%) [95% CI] 3 (12) [3–31] 135 (13) [11–16] 3 (19) [4–46] 88 (14) [11–17]
Complete response, n (%) 1 (4) 29 (3) 1 (6) 23 (4)
Disease control rate, % (95% CI) 40 (21–61) 40 (37–43) 44 (20–70) 41 (37–45)
CI = confidence interval; NE = not evaluable; OS = overall survival; PFS = progression-free survival * All patients except those in subgroups excluded from the IMvigor211 phase
III trial
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enzyme elevations and one case of autoimmune hepatitis).
Median OS in the Swiss subgroup was in the same range as
in the global population. Median OS in the Swiss IMvig-
or211-like subgroup was a remarkable 18.0 months, al-
though these results should be interpreted with particular
caution given the very small sample size (n = 16). The
response rate in the Swiss subgroup was 12%, consistent
with the 13% rate in the global population, and in 60% of
patients the best response was disease progression, high-
lighting the need for better patient selection or develop-
ment of better therapeutic approaches (e.g., atezolizumab
plus chemotherapy or novel/alternative immunotherapeu-
tic agents). However, 20% of patients remained on treat-
ment for >20 cycles. Furthermore, as shown in fig. 1, sus-
tained clinical benefit was observed in several patients
whose best response was stable disease, including one pa-
tient with CNS metastases and one with small-cell carcino-
ma. Interestingly, several patients continued atezolizumab
beyond progression. Post-hoc analyses from the IMvig-
or210 study suggest prolonged clinical benefit from this
approach [10], although this strategy has not been evaluat-
ed in a randomised trial.
Although the median OS of 18.0 months in the IMvig-
or211-like patients within the SAUL population is impres-
sive, it contrasts markedly with outcomes in some of the
non-IMvigor211-like patients typically excluded from
clinical trials. As in the global population, the patient with
ECOG performance status 2 had a very poor outcome,
reflecting clinical experience and highlighting the unmet
medical needs of these patients. On the other hand, the pa-
tient with CNS metastases appeared to achieve sustained
disease control. Greater insight into outcomes in special
populations can be gained from analyses of the global pop-
ulation focusing on patients with autoimmune disease [11]
or upper tract carcinoma [12], and elderly patients [9].
The present analysis reports outcomes of a defined group
of patients from a homogeneous health insurance system.
We hypothesised that the impact of equal access to Swiss
health resources would be of interest in comparison to the
full cohort of patients recruited worldwide in the SAUL
study. The remarkably long median OS in the IMvig-
or211-like patients enrolled in Switzerland may reflect the
intensified specialist palliative care in the participating
Swiss centres compared with some of the global centres
enrolling into the SAUL study. Non-Swiss patients were
enrolled from centres in Italy, Spain, Australia, Germany,
Greece, the UK, the Netherlands, Hungary, Brazil, Bel-
gium, Denmark, Romania, Poland, Austria, Canada, Ire-
land, Portugal, Croatia, India, Lithuania, the Czech Re-
public, Russia, Slovakia, Argentina, Colombia, Taiwan,
Lebanon, Saudi Arabia, China, Bulgaria and Estonia. With
such diversity, the likelihood of differences between coun-
tries in post-study care is high, but bias in patient selection
may also contribute, with some countries favouring enrol-
ment of patients in ‘special populations’ for whom there
are no other options, and others treating patients who
would have been eligible for typical clinical trials but do
not have access to atezolizumab in their healthcare sys-
tems. Outcomes in the subgroup of patients treated in the
UK have been presented [13]; others may be reported, al-
though unlikely from countries enrolling very small num-
bers of patients.
The relatively early enrolment of the Swiss patients com-
pared with the rest of the population may also contribute
to slight differences in OS, not only because of the longer
median follow-up but also because of the increased op-
portunity for further lines of therapy, which may influence
OS. On the other hand, with such small patient numbers
and overlapping CIs, we should not overinterpret any nu-
merical differences that may arise by chance. The protocol
did not specify particular treatments after progression and
therefore post-study treatment may reflect differences in
standard of care between countries. Further insight may
emerge at the final analysis, expected 4 years after enrol-
ment of the last patient in the global population.
To date, efforts to identify those patients most likely to de-
rive long-term benefit from atezolizumab – or from check-
point inhibitors more generally – have unfortunately been
largely unsuccessful. PD-L1 status appears to be impor-
tant: in SAUL, patients with a PD-L1 immunohistochem-
istry score of IC 2/3 showed longer OS (median 11.6
months) than those with a score of IC 0/1 (median 7.9
months) [9], although in a single-arm study, prognostic and
predictive effects cannot be differentiated. In the IMvig-
or211 trial, median OS was longer in the PD-L1 IC 2/3
subgroup than in the intention-to-treat population in both
the atezolizumab arm and the chemotherapy arm [6]. The
very small sample size and low event rate in the present
Swiss subgroup analysis prevent meaningful interpretation
of outcome according to PD-L1 status. It is critical to con-
tinue efforts to identify robust and reliable biomarkers for
immunotherapeutic agents, not only to identify patients
most suited to treatment, but also to spare those unlikely to
respond from ineffective treatment.
In conclusion, atezolizumab is an active treatment option
for platinum-pretreated patients with metastatic urothelial
carcinoma in Switzerland, even in difficult-to-treat scenar-
ios such as CNS metastases. Experience from this real-
world population is consistent with results from controlled
clinical trials in more selected populations. On the basis
of our present knowledge, it is reasonable to offer second-
line atezolizumab to all patients with metastatic urothelial
carcinoma whose disease relapses after first-line platinum-
based chemotherapy. In Switzerland, alternative registered
options (not available at the time of the SAUL study) now
include pembrolizumab, atezolizumab and nivolumab, as
well as re-exposure to platinum/gemcitabine if patients
were responding and had PFS of ≥6 months after initial
therapy with these agents. Further options include vinflu-
nine and taxanes, but these are proven to be inferior to im-
munotherapy. Median OS with vinflunine was 6.9 months
in the phase III trial versus best supportive care [14]. No
head-to-head trial has compared the different immunother-
apy options. The SAUL study and also the Swiss cohort
of SAUL suggest that all subgroups of patients can derive
clinical benefit from atezolizumab, regardless of pre-exist-
ing adverse clinical features that often tend to bias our rou-
tine treatment selection. Inclusion of populations typically
excluded from clinical trials and for whom there are little
or no data in the literature provides important new infor-
mation on the role of atezolizumab in clinical practice.
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